Hemogenyx Pharmaceuticals (LON:HEMO) Trading Up 10.3% - Here's What Happened

Key Points

• Hemogenyx Pharmaceuticals (LON:HEMO) was up 10.3%, trading as high as GBX 1,040 and last at GBX 1,010 on Monday with ~41,022 shares changing hands (a 24% increase vs. the average of 33,059) after a prior close of GBX 916.
• Preclinical-stage biotechnology focused on blood-disease therapies, including a CDX bi-specific antibody for relapsed/refractory AML, a HEMO-CAR-T candidate, and a stem-cell product for bone marrow/hematopoietic stem cell transplants.
• Financial snapshot: market capitalization £64.89 million, negative PE (-4.37), current ratio 0.43, quick ratio 6.72, debt-to-equity -440.54, and 50-/200-day moving averages of GBX 922.49/GBX 884.97 (beta 1.56).

Hemogenyx Pharmaceuticals Plc (LON:HEMO - ) was up 10.3% on Monday . The stock traded as high as GBX 1,040 and last traded at GBX 1,010. Approximately 41,022 shares traded hands during mid-day trading, an increase of 24% from the average daily volume of 33,059 shares. The stock had previously closed at GBX 916.

Hemogenyx Pharmaceuticals Price Performance

The company has a current ratio of 0.43, a quick ratio of 6.72 and a debt-to-equity ratio of -440.54. The firm has a market capitalization of £64.89 million, a PE ratio of -4.37 and a beta of 1.56. The business has a 50-day moving average of GBX 922.49 and a 200 day moving average of GBX 884.97.

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.